Corticosteroid therapy for COVID-19

Pulakurthi, Yashwitha Sai; Pederson, John M.; Saravu, Kavitha; Gupta, Nitin; Balasubramanian, Prasanth; Kamrowski, Shelby; Schmidt, Megan; Vegivinti, Charan Thej Reddy; Dibas, Mahmoud; Reierson, Natalie L.; Pisipati, Sailaja; Joseph, Betsy Ann; Selvan, Pragadeesh Thamarai; Dmytriw, Adam A.; Keesari, Praneeth Reddy; Sriram, Varsha; Chittajallu, Spandana; Brinjikji, Waleed; Katamreddy, Rewanth R.; Chibbar, Richa; Davis, Amber R.; Malpe, Manashree; Mishra, Hemant Kumar; Kallmes, Kevin M.; Hassan, Ameer E; Evanson, Kirk W.

doi:10.1097/md.0000000000025719

Cited by 37 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, it was not considered in further studies [ 54 , 55 , 56 , 57 ]. Deflazacort, a corticosteroid, was left out, as several corticosteroids are already in clinical trials and are being used clinically due to their anti-inflammatory properties in treating COVID-19 complications [ 58 , 59 ]. Cefaclor and other cephalosporin antibiotics were strongly considered but ultimately not included.…”

Section: Discussionmentioning

confidence: 99%

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

MacRaild

Mohammed

Faheem

et al. 2022

IJMS

View full text Add to dashboard Cite

SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5 million lives worldwide, devastating the economy and overwhelming healthcare systems globally. The development of new drug molecules and vaccines has played a critical role in managing the pandemic; however, new variants of concern still pose a significant threat as the current vaccines cannot prevent all infections. This situation calls for the collaboration of biomedical scientists and healthcare workers across the world. Repurposing approved drugs is an effective way of fast-tracking new treatments for recently emerged diseases. To this end, we have assembled and curated a database consisting of 7817 compounds from the Compounds Australia Open Drug collection. We developed a set of eight filters based on indicators of efficacy and safety that were applied sequentially to down-select drugs that showed promise for drug repurposing efforts against SARS-CoV-2. Considerable effort was made to evaluate approximately 14,000 assay data points for SARS-CoV-2 FDA/TGA-approved drugs and provide an average activity score for 3539 compounds. The filtering process identified 12 FDA-approved molecules with established safety profiles that have plausible mechanisms for treating COVID-19 disease. The methodology developed in our study provides a template for prioritising drug candidates that can be repurposed for the safe, efficacious, and cost-effective treatment of COVID-19, long COVID, or any other future disease. We present our database in an easy-to-use interactive interface (CoviRx that was also developed to enable the scientific community to access to the data of over 7000 potential drugs and to implement alternative prioritisation and down-selection strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

MacRaild

Mohammed

Faheem

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Hence, it was not considered further studies [45][46][47][48]. Deflazacort, a corticosteroid, was left out, as several corticosteroids are already in clinical trials and are being used clinically due to their anti-inflammatory properties in treating COVID-19 complications [49,50]. Cefaclor and other cephalosporin antibiotics were strongly considered but ultimately not included.…”

Section: Discussionmentioning

confidence: 99%

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

MacRaild¹,

Mohammed²,

Faheem³

et al. 2022

Preprint

View full text Add to dashboard Cite

SARS-CoV-2, is the cause of the COVID-19 pandemic which has claimed more than six million lives worldwide, devastating the economy and overwhelming healthcare systems globally. The development of new drug molecules and vaccines has played a critical role in managing the pandemic; however, new variants of concern still pose a significant threat as the current vaccines cannot prevent all infections. This situation calls for the collaboration of biomedical scientists and healthcare workers across the world. Repurposing approved drugs is an effective way of fast-tracking new treatments for recently emerged diseases. To this end, we have assembled and curated a database consisting of 7817 compounds from the Compounds Australia Open Drug collection. We developed a set of eight filters based on indicators of efficacy and safety that were applied sequentially to down-select drugs that showed promise for drug repurposing efforts against SARS-CoV-2. Considerable effort was made to evaluate approximately 14000 assay data points for SARS-CoV-2 FDA/TGA-approved drugs and provide an average activity score for 3539 compounds. The filtering process identified 12 FDA approved molecules with established safety profiles that have a plausible mechanism for treating COVID-19 disease. The methodology developed in our study provides a template for prioritising repurposable drug candidates that are safe, efficacious, and cost-effective for the treatment of COVID-19, long COVID, or any other future disease. We present our database in an easy-to-use interactive interface (CoviRx, https://www.covirx.org/) that was also developed to enable scientific community to access to the data of over 7000 potential drugs and to implement alternative prioritisation and down-selection strategies.

show abstract

“…It is well known that corticosteroids have a good anti-inflammatory effect. Studies have shown that corticosteroids therapy can also improve the mechanical ventilation of severe COVID-19 patients and has lower mortality than patients with routine nursing [112]. In short, there are still many clinical studies related to antiviral therapy.…”

Section: Antiviral Therapymentioning

confidence: 99%

Effects of COVID-19 on Arrhythmia

Zhan

Yue

Liang

et al. 2022

JCDD

View full text Add to dashboard Cite

The World Health Organization announced that COVID-19, with SARS-CoV-2 as its pathogen, had become a pandemic on 11 March 2020. Today, the global epidemic situation is still serious. With the development of research, cardiovascular injury in patients with COVID-19, such as arrhythmia, myocardial injury, and heart failure, is the second major symptom in addition to respiratory symptoms, and cardiovascular injury is related to the prognosis and mortality of patients. The incidence of arrhythmia in COVID-19 patients ranges from 10% to 20%. The potential mechanisms include viral infection-induced angiotensin-converting enzyme 2 expression change, myocarditis, cytokine storm, cardiac injury, electrophysiological effects, hypoxemia, myocardial strain, electrolyte abnormalities, intravascular volume imbalance, drug toxicities and interactions, and stress response caused by virus infection. COVID-19 complicated with arrhythmia needs to be accounted for and integrated in management. This article reviews the incidence, potential mechanisms, and related management measures of arrhythmia in COVID-19 patients.

show abstract

Corticosteroid therapy for COVID-19

Cited by 37 publications

References 28 publications

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

Systematic Down-Selection of Repurposed Drug Candidates for COVID-19

Effects of COVID-19 on Arrhythmia

Contact Info

Product

Resources

About